Breast Cancer

Melissa Drew is an international keynote speaker and award-winning data and digital transformation consultant focusing on how AI technologies impact procurement and supply chain organizations. She has received numerous awards from Top 25 Global Consultants, Top Data Voice in North America, to Women Thought Leaders to follow in 2023. Melissa’s' priorities include running after twin teenagers, educating our next-generation workforce, and providing more opportunities for women's voices to be heard at conferences. A recent Cancer Warrior, Melissa was diagnosed with Stage 3 breast cancer in Jan 2022 and is currently cancer-free. A force to be reckoned with, she continues to break down barriers and share her knowledge and lesson's learned freely.

Breast Cancer Awareness

Professor Charles Coombes, Professor of Medical Oncology, Imperial College London. He is also Hon Consultant Medical Oncologist, Imperial College Healthcare Trust. From October 2010 Professor Coombes is Director of The Imperial CRUK Cancer Centre. He is also Chair of The Imperial Cancer Research (UK) Centre Steering Committee and Theme leader for Cancer, Imperial College London He is engaged in developing novel methods for prediction of response to endocrine therapy in breast cancer and also carrying out research aimed at understanding the mechanisms of resistance to endocrine therapy and development of novel anti-cancer drugs.

Molecular signals controlling aberrant growth of breast cancer cells with specific focus on the oestrogen receptor and allied cell signalling pathways

Dr Kyriakos Kalogerakos has completed his Degree in Medical School from Breast Unit of Metaxa Hospital, Greece

Breast Cancer Research

Indira Poola has completed her PhD in Biochemistry from Mysore University, Mysore, India and post-doctoral training at the University of Michigan and Cornell University in the USA. She served as a Professor in Biochemistry and Molecular Biology and Surgery at Howard University Medical School, Washington, D.C. USA for 17 years. She is currently President of Silbiotech, Inc., in Gaithersburg, MD, USA. She has won 27 grant awards from 9 funding agencies totaling over $8Million. She has published more than 40 papers in highly reputed journals and has served as an adhoc reviewer for 24 journals. She has served as an adhoc grant reviewer for 10 different agencies including NIH, DoD, NSF, EPA, and Komen for the Cure.

Receptors, Cancer biomarkers all areas of biochemistry

Dr. Wiseman brings more than 40 years of academic and clinical experience to Bria Cell Therapeutics Corp. As Co-Founder of Bria Cell, he is the inventor for most of the Company’s intellectual property and actively participates in its ongoing technology development. During his career, Dr. Wiseman has managed numerous clinical development teams and programs, with a focus in oncology, tumor immunology, vaccine development, and genetics. He was previously the principal investigator for immunotherapy treatment protocols at the St. Vincent Cancer Treatment Center and the Los Angeles Oncologic Institute. As the former Director of the Breast Cancer Basic Research Laboratory at the University of Texas M.D. Anderson Hospital in the 1970s, Dr. Wiseman was one of the pioneers of the field of cancer vaccine therapeutics. Dr. Wiseman is Clinical Professor of Medicine at the Division of Medical Oncology, Keck-USC School of Medicine, and previously was Acting Chief of the Division of Oncology/Hematology at White Memorial Medical Center.

Oncology, tumor immunology, vaccine development

Dr. El Hadji Seydou Mbaye was born in 1978 in Kaolack a region of Senegal. During 2008-2013, he earned his PhD in Biology and Human Pathologies with the collaboration of the International Agency for Research on Cancer / World Health Organization, (IARC/WHO), Lyon (France); He obtained a Master’s of Life and Health, Specialty Biology of microorganisms, Virology; a Master’s of Life and Health, option Immuno-physiopathology; a License of Biochemistry in Louis Pasteur University of Strasbourg (France); and a General Degree in Sciences and Technologies in University of METZ (France). He was certified Grade 10/10 by the Federation International of Gynecology Obstetric (FIGO), the Accreditation Council of Oncology in Europe (ACOE), and the Institute Catalan of Oncology (ICO). These credits were recognized as Physician’s Recognition Award (AMA PRA Category 1) by the American Medical Association. He was awarded as International Outstanding Scientist Awards 2020, Awarded as the Best Researcher Award 2021, by VDGOOD. He was certified, by the United Nations, by IARC/WHO. He has published 1 Book with a style of philosophical story. Author of the World Program against Cancer in Low and Middle Incomes Countries, he is lead author of more than 90 peer-reviewed research articles published in reputed journals. Dr. Mbaye is Editor-in-Chief of 4 journals, Editorial Board Member of 157 International Journals, and then he has Edited/Reviewed 270 peer-reviewed articles. He is member of Allied Academies, member of the World Society for Virology (WSV), member of World’s Leading Virologists Group: Facing to Covid-19, member of U.S. National Academies of Sciences, Engineering, and Medicine (NASEM): Societal Experts Action Network (SEAN), and also, member of BCNet International Working Group, IARC/WHO. Dr. MBAYE has formed for free, more than 250 Healthcare Professionals for the techniques of cervical cancer screening in Senegal. He has screened for free more than 2000 women for cervical cancer in Senegal. He appeared on local media, 2S TV, Leeral.net, Mbour TV, Sen TV and 7TV.

Oncology

Dr. Shahla Masood is a Persian-born physician, who currently holds the positions of Professor and Chair of the Department of Pathology at University of Florida College of Medicine – Jacksonville and Chief of Pathology and Laboratory Medicine at Shands Jacksonville.She is the founder and Editor-in-Chief of The Breast Journal, the founder and past president of the “International Society of Breast Pathology,” the Director of the “Annual Multidisciplinary Symposium on Breast Disease”, “The Breast Cancer Public Forum”, and is currently the President of “The World Society for Breast Health.” She has been named as one of the Top Doctors in America and one of the 20 Top Professors in Oncology at an international level. Dr. Masood is a patient advocate, a partner in community affairs and an accomplished artist and gourmet chef.

She is the founder and Editor-in-Chief of The Breast Journal, the founder and past president of the “International Society of Breast Pathology,” the Director of the “Annual Multidisciplinary Symposium on Breast Disease”, “The Breast Cancer Public Forum”, and is currently the President of “The World Society for Breast Health.”

Marie Wood, MD is professor of medicine, deputy director of the hematology/Oncology Division and director of the Familial Cancer Program. She is a member of the ASCO Prevention Subcommittee and Vice Chair for the CALGB/AIIiance Prevention Committee. Dr. Wood's research focuses around cancer genetics and breast cancer prevention. She has done studies on the barriers to utilization of cancer genetics by primary care providers and recent work has focused on the definition of an adequate family history for oncology professionals. Dr. Wood has received national and local funding to evaluate the link between breast density and vitamin D in women at risk for breast cancer. She is chair of a national (CALGB/AIIiance) study evaluating this effect. Additional studies focus on risk factors for breast cancer and chemoprevention studies of the effects of statins on breast cancer biomarkers such as breast density, various serum and tissue biomarkers.

She is chair of a national (CALGB/AIIiance) study evaluating this effect. Additional studies focus on risk factors for breast cancer and chemoprevention studies of the effects of statins on breast cancer biomarkers such as breast density, various serum and tissue biomarkers.

Yvone Paterson is Professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, USA. As a Professor of Microbiology, Paterson is an active educator and trainer and is the PI of several training grants and programs. Her research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system. She has pioneered the application of this organism in vaccine development for over 20 years. Her laboratory was the first to show that this bacterium could be genetically engineered to target antigens to the MHC class I pathway for antigen processing with the induction of cytotoxic T cells, the first to show that it could provide protective immunity against viral challenge and the first to apply the technology for the immunotherapy of cancer. In partnership with Advaxis Inc., a company she founded in 2002, the Listeria based technology is now in a number of clinical trials. Overall, these trials have shown that Listeria based immunotherapeutics are safe to use in humans and result in significantly prolonged survival and, in some cases, complete and partial remissions.

Yvone Paterson research is in the field of cancer vaccines where she was the first investigator to use Listeria monocytogenes, as a vector to target tumor-associated antigens to the immune system.

Aysegul A. Sahin is a Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center. she has done Degree-Granting Education in 1980 at University of Ankara School of Medicine, Ankara, Turkey.

Aysegul A. Sahin is a Professor, Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center.

Zeina Nahleh is currently Professor of Internal Medicine and Chief of the Division of Hematology-Oncology at the Texas tech Health Sciences Center in El Paso, TX. She is also Co-Director of the Texas Tech Garbar Breast Care Center and Chairperson of the University Medical Center (UMC) Cancer Committee. DR Nahleh was previously employed as Associate Professor and Co-Leader of the Breast Cancer Multidisciplinary team at the Wayne State University- Barbara Ann Karmanos Cancer Institute, aNational Cancer Institute(NCI) - designated Cancer Center. Dr Nahleh’ s research interests, funded by the National Cancer Institute (NCI), the Cancer Prevention Institute of Texas (CPRIT) and several scientific agencies, focus on innovative treatment of breast cancer and improvingthe quality of life of cancer patients. Dr Nahleh is a principal investigator in the Southwest Oncology Group (SWOG) and a member of the NCI- Neoadjuvant and Metastatic breast committees. She is also a member of the American Society of Clinical Oncology and the American College of Physicians. Dr Nahleh has received numerous awards including the Barbara Ann Karmanos‘sHero of Breast Cancer Award, and the TTUHSC –EP Dean’s Excellence in Research Award. She has authored over 50 articles, books and book chapters in the field of cancer and breast cancer research. She has presented in major national and international cancer meetings and serves on the editorial board of numerous world -renowned medical journals.

Nahleh’s research interests, funded by the National Cancer Institute (NCI), the Cancer Prevention Institute of Texas (CPRIT) and several scientific agencies, focus on innovative treatment of breast cancer and improvingthe quality of life of cancer patients.

Alahari Suresh obtained his Bachelor of Science in Biology and Master of Science in Human Genetics from India in 1983 and 1986 respectively. His Ph.D. in Molecular Biology was awarded by Drexel University, Philadelphia in the year 1994. From 1994 to 1998, Dr. Alahari did a post-doctoral fellowship at the University of North Carolina at Chapel Hill. Since 1998, he has been a faculty member at the University of North Carolina and in 2004 joined the LSUHSC as Associate Professor of the Department of Biochemistry. During his tenure at the University of North Carolina, he discovered a novel protein that he termed, Nischarin. Dr. Alahari has published several papers describing the function of Nischarin. He has served on editorial review boards and study sections. In addition he availed visiting professorships at the University of Pennsylvania, Philadelphia and Rockefeller University, New York. Currently he holds endowed professorship named Fred Brazda Professorship.

He has served on editorial review boards and study sections. In addition he availed visiting professorships at the University of Pennsylvania, Philadelphia and Rockefeller University, New York. Currently he holds endowed professorship named Fred Brazda Professorship.

Yan-gao Man holds a medical doctor degree in Western Medicine and Master degree in Cell Biology and Microbiology from China, and a PhD in Cell Biology and Anatomy from USA. He received postdoctoral training in Cancer Biology at the American National Cancer Institute. After receiving his PhD in 1998, he has authored and co-authored over 200 published scientific and 46 non-scientific articles, and received 18 research grants and 3 patent certificates. He served as the Director of Gynecologic and Breast Research Laboratory of Armed Forces Institute of Pathology and American Registry of Pathology from 1995 to 2011. Currently, he serves as the Director of Research Laboratory and International Collaboration at Bon Secours Cancer Institute. He is also the editor-in-chief of a SCI (Journal of Cancer) and four newly launched international medical journals. His main research interest focuses on the mechanism of cancer invasion and metastasis. He is the author of the world most updated theories for cancer invasion and metastasis. His theory of cancer invasion has been regarding as more compatible with existing data than the traditional theory. Among all major theories of cancer metastasis, his theory is the only one that can explain all steps of metastasis.

Yan-gao Man main research interest focuses on the mechanism of cancer invasion and metastasis.

Dr. Kumar received his Ph.D. degree in Neuro-toxicology and is currently a Professor of Biochemistry at The Commonwealth Medical College, Scranton, PA, USA. Dr. Kumar’s research area is focused on the therapeutic targeting of the steroid receptors (SRs) for endocrine-related cancers. Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies. In addition to more than 100 publications to his credit, Dr. Kumar has also served as Editorial Board member of more than two-dozen scientific journals, and as expert reviewer on more than two-dozen grant review panels.

Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies.

Updating soon...

Updating soon...

Jin Cheng has completed his MD and PhD from Beijing Capital Medical University and Paris University XIII in 1986 and 1994, respectively. Following his postdoctoral training at Fox Chase Cancer Center in Philadelphia, he was recruited by Moffitt Cancer Center as an assistant professor in 1997. Currently, he is professor and interim chair of Deportment of Molecular Oncology at Moffitt Cancer Center. He has published more than 130 papers in highly respected journals and has been serving as an editorial board member of in several journals.

He has published more than 130 papers in highly respected journals and has been serving as an editorial board member of in several journals.